je.st
news
Tag: evaluating
Celladon Merger: A Win/Win/Win For All: Evaluating Existing Shareholders' Choices
2015-12-02 19:07:10| Trucking - Topix.net
Existing Celladon shareholders can exit at a share price reflecting full net cash backing or continue in a company with future prospects. Merger route allows choice on realizing capital gains/losses.
Tags: existing
choices
evaluating
shareholders
Evaluating 4 Emerging Prospects In Online Retail Banking
2015-11-30 20:56:54| IT Services - Topix.net
Benchmarked the performance of four online banks against the Big Four . Ally Bank stood out for its exceptional customer experience, modest deposit growth, and asset quality that rivaled the Big Four.
Tags: online
retail
banking
emerging
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA (pembrolizumab) for Advanced Gastric Cancer
2015-10-22 13:30:46| Merck.com - Product News
Dateline City: ROCKVILLE, Md. and KENILWORTH, N.J. Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer ROCKVILLE, Md.and KENILWORTH, N.J. Language: English read more
Tags: advanced
study
combination
cancer
Latest on VW Diesel Scandal: Evaluating Resale Impact and Lawsuits Galore
2015-10-08 02:00:46| AutomotiveDigest.com - Automotive Industry News
Details on the Volkswagen recall of its diesel-powered cars sold in the U.S. is still in the early stages. Heres a few news developments and market analysis on where it all stands for now Certified pre-owned sales saw a big year-over-year drop in September at nearly 17%, while the first nine months had seen a […] The Article Latest on VW Diesel Scandal: Evaluating Resale Impact and Lawsuits Galore appeared first on Automotive Digest.
Tags: latest
impact
diesel
evaluating
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »